The use of controlled psychedelic medicines has increased in popularity over the last few years.   Even here in the Lehigh Valley, we have a community that supports  our psychonauts. These substances are believed to have the potential to help individuals suffering from conditions such as depression, anxiety, and PTSD (post-traumatic stress disorder).

That being said, energy work can help to explain and integrate the intense experience of plant medicine. 

Here is a list of companies listed on the New York Stock Exchange that are deciding how best to manage the production and administration of psychedelic drugs. 

• ATAI Life Sciences (NASDAQ:ATAI) By pooling resources and best practices, we aim to responsibly accelerate the development of new medicines across our business entities, seeking to more effectively treat and ultimately heal mental health disorders.
• Compass Pathways (NASDAQ:CMPS)

  COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first programme is researching how COMP360 psilocybin therapy could help people with treatment-resistant depression.

  We want to transform the patient experience in mental health care.

• Seelos Therapeutics (NASDAQ:SEEL) 
• Numinus Wellness (OTC:NUMIF) Numinus Received Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
• Revive Therapeutics (OTC:RVVTF) 
• Mind Medicine (NASDAQ:MNMD) 
• GH Research (NASDAQ:GHRS) GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD)
• Cybin (AMEX:CYBN) Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics.